Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential

Molecular Genetics and Metabolism

Volumn 75, Issue 3, 2002, Pages 250-259

  Wirsching, Frank ^a   Luge, Cornelia ^b   Schwienhorst, Andreas ^a  

^a Inst fuer Mikrobiologie und Genetik   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

Anticoagulative activity; Fusion protein; Hirudin; Modular protein design; Plasminogen activator; Staphylokinase; Thrombin inhibitor; Thrombolysis

Indexed keywords

AMINO ACID; CHIMERIC PROTEIN; CHROMOGENIC SUBSTRATE; HYBRID PROTEIN; PLASMINOGEN ACTIVATOR; STAPHYLOKINASE; THROMBIN INHIBITOR;

AMINO ACID SEQUENCE; ARTERIAL BLOOD; ARTICLE; BINDING AFFINITY; BLOOD CLOT LYSIS; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; ELECTRIC POTENTIAL; ESCHERICHIA COLI; FIBRINOLYSIS; GENE EXPRESSION; GENE SEQUENCE; LYSIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RACEMIC MIXTURE; THROMBOCYTE RICH PLASMA;

EID: 0036353340     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2001.3292     Document Type: Article

References (51)

1. Basic and clinical aspects of fibrinolysis and thrombolysis
2. On the future of thrombolytic therapy for acute myocardial infarction
3. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation
4. The clot thickens: Clues provided by thrombin structure
5. Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion
6. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential
7. Importance of modulating balance of procoagulant and fibrinolytic activity to success of antithrombotic therapy
8. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates
9. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir)
10. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion
11. Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential
12. Covalent linkage of streptokinase to recombinant hirudin: A novel thrombolytic agent with antithrombotic properties
13. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction
14. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase
15. 2-terminal proteolysis for plasminogen activation
16. NMR secondary structure of the plasminogen activator protein staphylokinase
17. New antithrombotic agents for the prevention and treatment of deep vein thrombosis
18. Advances in antithrombotic therapy: Novel agents
19. Safety and efficacy of recombinant hirudin (CGP-39393) versus heparin in patients with stable angina undergoing coronary angioplasty
20. Die isolierung und chemische charakterisierung des hirudins
21. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis
22. Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis
23. Display of functional thrombin inhibitor hirudin on the surface of phage M13
24. The structure of a complex of recombinant hirudin and human α-thrombin
25. Cloning and expression in Escherichia coli of a syntetic DNA for hirudin, the blood coagulation inhibitor in the leech
26. Expression and secretion in S. cerevisiae of biologically active leech hirudin
27. Contribution of the N-terminal region of hirudin to its interaction with thrombin
28. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
29. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin
30. High yield production and purification of recombinant staphylokinase for thrombolytic therapy
31. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction
32. Cleavage of structural protein during assembly of the head of bacteriophage T4
33. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion
34. On the mechanism of fibrin-specific plasminogen activation by staphylokinase
35. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity
36. Clot-bound thrombin is protected from inhibition by heparin-antithrombin-III but susceptible to inactivation by antithrombin-III-independent inhibitors
37. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
38. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial
39. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study - A study of the arbeitsgemeinschaft-leitender-kardiologischer-krankenhausärzte
40. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trial
41. Effects of recombinant hirudin (HBW 023) on early and late coronary patency in acute myocardial infarction patients treated with streptokinase (the HIT-Sk study)
42. A strong thrombin-inhibitory prourokinase derivative with sequence elements from hirudin and the human thrombin receptor
43. Anticoagulant activity of synthetic hirudin peptides
44. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization
45. Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction
46. Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage
47. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
48. CX-397, a novel recominant hirudin analog having a hybrid sequence of hirudin variants-1 and -3